Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Martee Leigh Hensley, Danielle Enserro, Helen Hatcher, P. B. Ottevanger, Anders Krarup-Hansen, Jean-Yves Blay, Cyril Fisher, Katherine M. Moxley, Shashikant B. Lele, Jayanthi Sivasothy Lea, Krishnansu Sujata Tewari, Premal H. Thaker, Oliver Zivanovic, David M. O'Malley, Katina Robison, David S. Miller
Institutions: Memorial Sloan Kettering Cancer Center, NRG Oncology, Cambridge University Hospitals NHS Foundation Trust, Radboud University Medical Center, Copenhagen University Hospital, Centre Léon Bérard, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, University of Oklahoma Health Sciences Center, Roswell Park Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of California, Irvine, Washington University in St. Louis, The Ohio State University, Women & Infants Hospital of Rhode Island
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891531638